Mr. Charles Joseph Micklosky Jr., R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1489 Sanbrook Ct, Bethlehem, PA 18015 Phone: 610-865-3370 Fax: 610-865-3370 |
Frank M Wang, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3036 Emrick Blvd, Bethlehem, PA 18020 Phone: 610-997-8460 Fax: 610-997-8462 |
Stacey Lauren Thomas Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3895 Adler Pl, Building A, Suite 120, Bethlehem, PA 18017 Phone: 800-422-6601 Fax: 610-867-1087 |
Julia Rose Bold Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 801 Ostrum St, Bethlehem, PA 18015 Phone: 610-390-9051 |
Hannah Do Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 817 E 4th St Apt 1, Bethlehem, PA 18015 Phone: 610-419-6522 |
Dr. Pratibha Patel, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2240 Schoenersville Rd, Bethlehem, PA 18017 Phone: 610-861-7494 Fax: 610-861-9028 |
News Archive
A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs. The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.
Personalized cancer treatment is one step closer to becoming a reality for more patients, thanks to a Cancer Council Beat Cancer Project grant awarded to the University of South Australia researcher Dr. Stephanie Reuter Lange to explore how computer-based modeling can optimize cancer treatment and remove the need for expensive clinical trials.
Atrial fibrillation is the most common heart arrhythmia in humans. This condition increases the risk of heart failure, stroke, dementia and death, and current treatments have suboptimal efficacy and carry side effects.
Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics' three currently available diagnostic tests.
› Verified 4 days ago